Targeting MYCN: A Good BET for improving neuroblastoma therapy?

Cancer Discovery

Volumn 3, Issue 3, 2013, Pages 255-257

  Schnepp, Robert W ^a   Maris, John M ^a,b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Abramson Family Cancer Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BROMODOMAIN AND EXTRATERMINAL PROTEIN; JQ 1; MYC PROTEIN; NOTCH RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CHROMATIN STRUCTURE; DNA METHYLATION; GENE ACTIVATION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; NEURAL CREST; NEUROBLASTOMA; ONCOGENE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TUMOR GROWTH;

ANIMALS; FEMALE; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 84876044693     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0018     Document Type: Article

References (11)

1. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74.
2. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-9.
3. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-73.
4. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-17.
5. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011; 108: 16669-74.
6. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
7. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-11.
8. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery Y H, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013;3:308-23.
9. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.
10. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985-95.
11. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-6.